Target Therapy in Hematological Malignances: New Monoclonal Antibodies.

ABSTRACT: Apart from radio- and chemotherapy, monoclonal antibodies (MoAbs) represent a new, more selective tool in the treatment of hematological malignancies. MoAbs bind with the specific antigens of the tumors. This interaction is a basis for targeted therapies which exhibit few side effects and significant antitumor activity. This review provides an overview of the functional characteristics of MoAbs, with some examples of their clinical application. The promising results in the treatment of hematological malignancies have led to the more frequent usage of MoAbs in the therapy. Development of MoAbs is a subject of extensive research. They are a promising method of cancer treatment in the future.

SUBMITTER: Podhorecka M 

PROVIDER: S-EPMC4897146 | biostudies-other | 2014

REPOSITORIES: biostudies-other